Zerbor /
22 December 2014Americas

Ibuprofen agreement signed with mystery healthcare company

US pharmaceutical company Strategic Science and Technologies (SST) has signed an option agreement with “one of the world’s largest over-the-counter (OTC) healthcare companies” to commercialise one of its ibuprofen products.

The product at the centre of the deal is a cream product containing ibuprofen, a drug targeted towards people suffering from acute pain. It uses SST’s drug delivery technology Knosis, which helps drugs overcome the skin’s protective barrier by helping it drive into the tissue.

The drug, which has been patented, is currently in advanced stages of clinical development and is still awaiting final approval from the Food and Drug Administration. It will be sold as an OTC drug.

Although the other healthcare company in the deal has so far not been named, nor has any financial details of the deal been disclosed, it has been confirmed that they will have exclusive rights to market the product as soon as it gains FDA approval.

Eric Fossel, chief executive at SST, said: “This transaction provides SST with a very strong commercial partner to bring this important product directly to individuals who suffer from acute pain.

“This partner’s leadership in marketing and manufacturing high-quality healthcare products provides us with the widest distribution at an accessible price,” he added.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at